Novo Ultra fast acting insulin FIAsp
Aug 27, 2014 20:06:39 GMT -5
thekindaguyiyam, 4Balance, and 3 more like this
Post by mnkdfan on Aug 27, 2014 20:06:39 GMT -5
Novo's ongoing ultra fast acting insulin (FIAsp) development program is another endorsement for Afrezza's unique value. Novo is pouring in hundreds of $millions in development hoping for a faster injected prandial insulin solution in trial III (completion estimate 1/2015) about the same time Afrezza becomes available to patients. Even if Novo was successful, they would not start selling till later 2016 where Afrezza would already have a 1.5yrs head start not to mention a painless delivery method.
I just find it frustrating (like many folks here) that with all the positive Afrezza attributes and approval risks removed coupled with a great partnership that the PPS is not significantly higher. I guess we just need to wait a few more quarters for sales to answer the final acceptance question. MNKD is not going to get the benefit of the doubt for future success (nothing new for this company). Why we do not have more institution ownership with seemingly a huge risk/reward in favor of success is baffling.
www.novonordisk-trials.com/Website/pdf/registry/nn12183853.pdf
MNKDFAN
I just find it frustrating (like many folks here) that with all the positive Afrezza attributes and approval risks removed coupled with a great partnership that the PPS is not significantly higher. I guess we just need to wait a few more quarters for sales to answer the final acceptance question. MNKD is not going to get the benefit of the doubt for future success (nothing new for this company). Why we do not have more institution ownership with seemingly a huge risk/reward in favor of success is baffling.
www.novonordisk-trials.com/Website/pdf/registry/nn12183853.pdf
MNKDFAN